Advisory Research’s Alnylam Pharmaceuticals ALNY Stock Holding History

Advisory Research’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,339	Closed	-$382K	–	373
2022 Q1	$382K	Sell	2,339 -750	-24%	-$114K	0.03%	280
2021 Q4	$524K	Sell	3,089 -213	-6%	-$39.6K	0.04%	253
2021 Q3	$623K	Buy	3,302 +650	+25%	+$122K	0.04%	233
2021 Q2	$450K	Buy	2,652 +519	+24%	+$76K	0.03%	275
2021 Q1	$301K	Buy	+2,133	New	+$321K	0.02%	305
2020 Q4	–	Sell	-3,164	Closed	-$461K	–	316
2020 Q3	$461K	Buy	3,164 +1,355	+75%	+$193K	0.04%	242
2020 Q2	$268K	Sell	1,809 -632	-26%	-$85.2K	0.02%	291
2020 Q1	$266K	Buy	+2,441	New	+$282K	0.02%	253
2018 Q2	–	Sell	-2,922	Closed	-$348K	–	364
2018 Q1	$348K	Buy	+2,922	New	+$377K	0.01%	335

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Advisory Research's ALNY Position: Q2 2022 in Review

Advisory Research sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 2,339 shares — an estimated $382K sold.

Advisory Research first reported a position in ALNY in Q1 2018 and held it in 9 quarters. The position peaked at $623K in Q3 2021. 423 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

Advisory Research reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Advisory Research sold 2,339 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $382K.
Advisory Research first reported a position in Alnylam Pharmaceuticals in Q1 2018 and held it in 9 quarters.
Advisory Research's Alnylam Pharmaceuticals position peaked at $623K in Q3 2021.
423 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Advisory Research's 13F filing for Q2 2022, filed 15 Aug 2022.